File

Stronghold Digital Mining, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock

Friday, October 22, 2021 - 9:05pm

The shares of Class A common stock began trading on The Nasdaq Global Market on October 20, 2021, under the ticker symbol SDIG.

Key Points: 
  • The shares of Class A common stock began trading on The Nasdaq Global Market on October 20, 2021, under the ticker symbol SDIG.
  • The net proceeds received by Stronghold from the offering (after deducting underwriting discounts and commissions and estimated offering expenses) were approximately $132.5 million.
  • Stronghold intends to contribute the net proceeds of this offering to Stronghold Digital Mining Holdings LLC (Stronghold LLC) in exchange for Class A common units of Stronghold LLC.
  • Stronghold LLC will use the proceeds for general corporate purposes, including for acquisitions of miners and power generating assets.

RASi, a Lexitas Company, Announces Acquisition of MyCompanyWorks, Inc.

Thursday, October 21, 2021 - 7:57pm

HOUSTON, Oct. 21, 2021 /PRNewswire/ --Registered Agent Solutions, Inc. "RASi", a Lexitas company, announced its acquisition of MyCompanyWorks, Inc.

Key Points: 
  • HOUSTON, Oct. 21, 2021 /PRNewswire/ --Registered Agent Solutions, Inc. "RASi", a Lexitas company, announced its acquisition of MyCompanyWorks, Inc.
  • "MyCompanyWorks has been a leader in providing entrepreneurs a convenient platform to form and manage their businesses.
  • "With its mission, reputation, and success, MyCompanyWorks was an obvious and natural choice for the establishment of our new Entrepreneurial Services Department."
  • Matt Knee, President of My Company Works said, "I couldn't be more excited to join the RASi family.

My Size Files Lawsuit Against the Lazar/Ault Activist Group Over Attempts to Mislead Stockholders and Wage an Unlawful Proxy Contest

Thursday, October 21, 2021 - 2:15pm

The suit seeks, among other things, to enjoin the Activist Group from misleading My Size stockholders and waging an illegal proxy contest to seize control of the Company's Board of Directors (the "Board").

Key Points: 
  • The suit seeks, among other things, to enjoin the Activist Group from misleading My Size stockholders and waging an illegal proxy contest to seize control of the Company's Board of Directors (the "Board").
  • Notably, My Size contends the Activist Group failed to disclose that the true purpose underlying its security purchases was to merge My Size with another company.
  • Ronen Luzon, Chief Executive Officer and Founder of My Size, commented:
    "The Board and management team have decided to take this extraordinary step to protect My Size for the benefit of all stockholders.
  • We firmly believe that the Activist Group has purposefully misled stockholders for its own benefit and in doing so, has violated the federal securities laws.

Stargaze Entertainment Group Inc (Stargaze Digital Books) Announces it has entered into a Global Distribution/License Agreement with Kitaboo

Thursday, October 21, 2021 - 2:28pm

VANCOUVER, BC, Oct. 21, 2021 /PRNewswire/ -- Stargaze Digital Books a division of Stargaze Entertainment Group Inc (the "Company") (OTC: STGZ) announces that it has entered in to a Global Distribution/License Agreement with KITABOO a premier digital platform (E-Book Reader) that allows content providers to sell/market their digital content/Books.

Key Points: 
  • VANCOUVER, BC, Oct. 21, 2021 /PRNewswire/ -- Stargaze Digital Books a division of Stargaze Entertainment Group Inc (the "Company") (OTC: STGZ) announces that it has entered in to a Global Distribution/License Agreement with KITABOO a premier digital platform (E-Book Reader) that allows content providers to sell/market their digital content/Books.
  • https://kitaboo.com/publishers/
    KITABOO; can plug into the Stargaze Digital Books application (SDB) to get a fully functional reader.
  • It is a toolbox that includes APIs, code and other rules for developing a feature-rich eBook reader.
  • Kitaboo supports rendering digital content like eBooks (reflowable & fixed layout ePUB and PDF) audio, video, HTML and is available for iOS, Android and Web.

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Thursday, October 21, 2021 - 1:30pm

21 October 2021, LONDON and NEW YORK -- Silence Therapeutics plc (AIM:SLN and Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, announces it is hosting its R&D Day in New York City today.

Key Points: 
  • Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • Silence will also provide an update on its growing discovery pipeline and plans to deliver 2-3 INDs per year from 2023.
  • Silence remains on-track to deliver 2-3 INDs per year from 2023 through both its proprietary and partnered mRNAi GOLD platform programs.

PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

Thursday, October 21, 2021 - 1:30pm

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans to present new updates on its pipeline during the 63rd American Society of Hematology Annual Meeting , December 11-14, 2021.

Key Points: 
  • PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans to present new updates on its pipeline during the 63rd American Society of Hematology Annual Meeting , December 11-14, 2021.
  • PharmaEssentia continues to enroll participants in the trial at sites throughout the United States and Asia, and has now expanded with new sites in Canada.
  • We are pleased to partner with these renowned MPN specialists to participate in this important study.
  • PharmaEssentia continues to build momentum with its pipeline to deliver new solutions in MPNs.

ATUM’s Leap-In Transposase® Technology Supports Successful AskGene Pharma IND Clearance in China

Thursday, October 21, 2021 - 1:00pm

The antibody was produced using the Leap-In Transposase technology pioneered by ATUM and represents the tenth successful IND clearance globally using this platform.

Key Points: 
  • The antibody was produced using the Leap-In Transposase technology pioneered by ATUM and represents the tenth successful IND clearance globally using this platform.
  • We are encouraged to see how fast the Leap-In Transposase technology has been broadly accepted in the marketplace.
  • AskGene Pharma was one of the earliest adopters of the Leap-In Transposase technology and we are excited to see how fast they have reached IND filing status.
  • The Leap-In Transposase technology enables rapid, stable, and robust manufacturing of mammalian cell lines for the production of commercial-grade protein pharmaceuticals.

Enthusiast Gaming Announces Updates For Addicting Games

Thursday, October 21, 2021 - 12:00pm

All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast Gaming anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information.

Key Points: 
  • All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast Gaming anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information.
  • Forward-looking statements in this news release include, but are not limited to, statements regarding content strategies, product development, and e-commerce capabilities.
  • While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect.
  • Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)

Wednesday, October 20, 2021 - 9:30pm

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am – 12:00pm ET.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am 12:00pm ET.
  • in a scientific discussion of the role of innate immune modulators in cancer treatment.
  • An archived copy of the webcast will be available on the Checkmate website for approximately 90 days after the event.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.

Absci Opens Door to New Biotechnology Campus

Wednesday, October 20, 2021 - 9:05pm

Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016, said Washington Governor Jay Inslee.

Key Points: 
  • Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016, said Washington Governor Jay Inslee.
  • I look forward to cutting the ribbon on Abscis new campus early next month, and to continuing to support the development of our biotechnology ecosystem here in Washington.
  • The new Absci facility was concepted and constructed in a close collaboration between the company, Portland design firm Bora Architecture & Interiors, and local contractor Bremik Construction.
  • Its inspiring to come to work each day in this exceptional building, said Sean McClain, founder and CEO of Absci.